PLM Fleet Opens New Branches in Rochester and Philadelphia
'PLM is proud to open these new branches in Philadelphia and Western New York, which marks a significant milestone in our commitment to be the leader in refrigerated fleet management,' said Jerry Keane, VP and General Manager, Rental.
PLM Fleet has the nation's largest and most diverse selection of refrigerated equipment, ranging in lengths from 28 to 53 feet, with single-temperature, multiple-temperature, or electric-only, including versatile liftgate options. Every rental includes PLM's On-Site Mobile maintenance and 24/7 emergency break-down service. PLM offers pick up and drop off service, and a dedicated team of in-house fleet managers. With the innovative PLMServiceCode™, customers can request and monitor all service requests, track repairs to completion, and view their trailer licensing and registration.
'PLM is proud to open these new branches in Philadelphia and Western New York, which marks a significant milestone in our commitment to be the leader in refrigerated fleet management,' said Jerry Keane, VP and General Manager, Rental. 'This expansion strengthens our ability to provide customers with more cost-effective and timely access to trailers, while offering a broad range of specifications tailored to meet the distinct operational needs of their businesses.'
The new PLM branches are located at:
8330 State Road, Philadelphia, PA 19136
1280 Jefferson Road, Rochester, NY 14623
PLM Fleet has a network of 35 branches in all the key markets nationwide. At all of PLM's branches, customers can rent equipment for a year, month or even one day. With over 15,000 units, PLM has the nation's largest and most versatile selection of refrigerated equipment. Known for innovating refrigerated fleet management, PLM can be found at plmfleet.com.
About PLM Fleet, LLC
PLM Fleet ® is the largest nationwide, technology-driven company dedicated to refrigerated trailer leasing and cold supply chain solutions. Located in the state-of-the-art fleet solutions center in Newark, NJ, PLM has the largest assortment of refrigerated trailers in the U.S. Visit plmfleet.com to review all the financing, technology and services that help our customers improve fleet and product lifecycle efficiencies and cost savings in the cold supply chain.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Steel Rebar Market worth $268.4 billion by 2030, at a CAGR of 4.0%, says MarketsandMarkets™
Delray Beach, FL, Aug. 11, 2025 (GLOBE NEWSWIRE) — The Steel Rebar Market was USD 212.9 billion in 2024, and it is projected to reach USD 268.4 billion in 2030, at a CAGR of 4.0%, registering a CAGR of 6.7% during the forecast period, as per the recent study by MarketsandMarkets™. Steel rebar, or reinforcing bar, is a steel rod used to strengthen concrete and masonry structures. It offers tensile strength, which concrete lacks, helping to prevent cracking and structural failure under tension. Rebar is usually made of carbon steel and comes in different grades, sizes, and surface finishes to enhance bonding with concrete. It is used in most building projects, bridges, and infrastructure to boost the durability, stability, and load-carrying capacity of reinforced concrete structures. Download PDF Brochure: Browse in-depth TOC on 'Steel Rebar Market' 309 – Market Data Tables 61 – Figures 290 – Pages List of Key Players in Steel Rebar Market: Nippon Steel Corporation (Japan) ArcelorMittal (Luxemberg) Gerdau S/A (Brazil) Nucor Corporation (US) Commercial Metals Company (US) TATA Steel (India) Steel Authority of India Limited (India) Mechel PAO (Russia) Steel Dynamics, Inc. (US) NLMK Group (Russia) JSW (India) Baosteel Group Co., Ltd. (China) Drivers, Opportunities and Challenges in Steel Rebar Market: Drivers: Expansion of urban mass transit systems across developing economies Restraint: Import tariffs and anti-dumping measures Opportunity: Green steel rebar from hydrogen-based DRI Challenge: Lack of recycling infrastructure in emerging economies Get Sample Pages: Key Findings of the Study: By end-use sector, the infrastructure segment accounted for the largest market share in 2024. By coating type, the plain carbon steel segment is projected to witness the highest CAGR during the forecast period. Asia Pacific accounted for the largest share of the market in 2024. The steel rebar market is divided by type, which includes deformed and mild. Deformed steel bars feature ribs, lugs, and horns on their surface to enhance the bond between concrete and the rebar, reducing the risk of concrete corrosion. They are widely used across various sectors, such as the construction industry, for building bridges and skyscrapers. Their superior tensile strength and durability have gained recognition worldwide for infrastructure and commercial construction. By contrast, mild steel rebar, which is smooth and has much lower tensile strength, is used for smaller projects like garden walls or reinforcing other types of temporary large structures. Although soft rebar is cheaper, its weak adhesion and tendency to slip have led to decreased use in recent years for new building materials. The steel rebar market is segmented by process into basic oxygen steelmaking (BOS) and electric arc furnace (EAF). The BOS process is the most commonly used method for steel production, primarily in regions with high steel demand and abundant virgin iron ore supplies. It is widely used by integrated steel plants for large-scale manufacturing. Meanwhile, the EAF route is quickly gaining popularity as a flexible, low-carbon option that recycles scrap steel. EAF is especially favored in sustainable steelmaking and circular economy applications. With strict environmental regulations and a plentiful supply of scrap, EAF is expected to grow faster in the steel rebar market. The steel rebar market is segmented by coating type into plain carbon steel rebar, galvanized steel rebar, and epoxy-coated steel rebar. Plain carbon steel rebar (ASTM A1044, available in ASTM A615, A706, A775, and A996) is made from unfinished-rolled steel and is the most common type of rebar. However, it lacks corrosion resistance, making it unsuitable for moist conditions. Galvanized steel rebar, which is zinc-coated, offers rust and corrosion resistance suitable for coastal or humid environments. Epoxy-coated steel reinforcement (ASTM A775) provides an effective solution for preventing corrosion of steel rebar and prolonging the lifespan of building structures. Increasing focus on infrastructure longevity and reducing maintenance costs is driving demand for coated rebar, especially zinc and epoxy-coated types. Get Customization on this Report: The steel rebar market is also segmented by bar size, which includes #3, #4, #5, #8, and other sizes. #3 rebar, being smaller, is used in light-duty construction such as reinforcing patios, driveways, and residential slabs. #4 and #5 rebar sizes are commonly used for these applications, balancing strength with ease of concrete placement in foundations, walls, and columns in both residential and commercial buildings. Conversely, larger #8 rebar is generally used for heavy-duty projects like bridges, large industrial facilities, and multi-story buildings requiring substantial load-bearing capacity. The selection of bar size depends on structural design, service conditions, and building code requirements for different types of structures. The steel rebar market is segmented based on end-use sector, which includes infrastructure, housing & industrial. The infrastructure vertical is a major revenue contributor due to the huge amount of government spending on roads, bridges, railways, and airports in developing countries. Steel rebar is a must in order to maintain the structure and integrity of these heavy concrete projects. Another significant source of contribution is the housing sector, which is driven by urbanization, population increase, and the requirement for affordable as well as tall apartments. The industrial segment sells steel rebar that is included in the construction of manufacturing plants, warehouses, coal and battery plants, and other industrial facilities. The rising industrialization and the development of energy and logistics systems have been demanding more in this segment. Rebar specifications and quantity are also affected by the specific construction requirements of each sector. The steel rebar market is studied in five regions: Asia Pacific, Europe, North America, the Middle East & Africa, and South America. Of these, Asia Pacific is leading the market and is projected to experience the fastest CAGR during the forecast period. This is driven by the rapid pace of urbanization, the development of large-scale infrastructure, and the significant government spending on transportation, energy, and housing in countries such as China, India, Indonesia, and Vietnam. Projects such as India's Smart Cities Mission and China's Belt and Road Initiative are driving steel rebar demand in the region. North America is a market that is relatively mature, with demand through rehabilitation of aging infrastructure and modernization, particularly in the US and Canada. The U.S. Infrastructure Investment and Jobs Act has increased demand for rebar for bridges, highways, and public transit systems. The market is also witnessing a growing preference for epoxy-coated and corrosion-resistant rebars in light of stringent construction and safety standards. Europe also indicates firm demand, driven by residential renovation, energy-efficient building construction, and earthquake-resistant buildings in Southern and Eastern Europe. South America, led by Brazil and Argentina, is slowly growing, fueled by public infrastructure projects and an increased demand for housing. But economic disruptions could out turn consistent development. The Middle East & Africa coupler for hollow structures market is proving to be a promising market. Continuation of mega projects, including construction sites for Saudi Arabia's NEOM city and UAE infrastructure development projects, rollout of Vision Plan 2021, and introduction of tourism and energy sources are expected to aid in the long-term demand for high-strength and durable steel rebar in the region. Browse Adjacent Markets Building and Construction Market Research Reports & Consulting Related Reports: Green Hydrogen Market Protective Packaging Market Building Thermal Insulation Market Silicone Elastomers Market Adhesives & Sealants Market Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
10 hours ago
- Business Wire
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. 'In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement from the U.S. FDA on the key elements of the Embolden™ registrational trial, in which we have already begun initiation activities,' stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. 'We are pleased to be moving forward with Embolden, which was purposefully and rigorously designed to differentiate NGN-401 by evaluating participants as young as three years of age with a primary endpoint that incorporates measures that KOLs, caregivers and payors believe to be clinically meaningful. Our previously announced reallocation of capital provides us runway into early 2028, enabling us to focus our resources on advancement of this potential therapy for the patients and families who urgently need new treatment options.' Dr. McMinn continued, 'In leveraging the continual dialogue under the START program, the FDA encouraged the analysis of the Embolden primary endpoint to remain at 12 months as the basis for full approval, noting that a 6-month endpoint may not be considered clinically meaningful. In further maintaining the rigorous design of the Embolden trial, we are electing to dose the last planned participant from the Phase 1/2 trial as part of the registrational Embolden trial and add one more participant to complete the proposed sample size at 20 patients.' Second Quarter 2025 and Recent Highlights, and Anticipated Milestones NGN-401 Gene Therapy for Treatment of Rett Syndrome Received written agreement from the U.S. Food and Drug Administration (FDA) on key elements of the Embolden registrational trial of NGN-401 and refined the sample size to propose 20 participants Initiated Embolden clinical trial activities to support the conversion of the Phase 1/2 trial to a registrational trial Completed enrollment in the Phase 1/2 trial, with the last 5 additional participants dosed in the first half of 2025 Remains on track to report updated clinical efficacy and safety data from the Phase 1/2 trial in the second half of 2025 Presented at scientific conferences the hemophagocytic lymphohistiocytosis (HLH) monitoring and treatment algorithm incorporated into the NGN-401 clinical trial, which has been acknowledged as valuable information by the Rett syndrome and gene therapy communities There has been no evidence of HLH/hyperinflammatory syndrome in any NGN-401 trial participant at the 1E15 vg dose level, as of the date of this press release Upcoming Events Stifel Biotech Summer Summit: Management will participate in a fireside chat at 12:00 p.m. ET on August 12 (not webcast) H.C. Wainwright Annual Global Investment Conference: Management will participate in a fireside chat at 2:30 p.m. ET on September 8 and participate in 1x1 meetings Second Quarter 2025 Financial Results Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 million. We currently expect cash, cash equivalents and short-term investments to fund planned operations into early 2028. Research & Development (R&D) Expenses: R&D expenses were $19.4 million for the three months June 30, 2025 compared to $15.7 million for the three months ended June 30, 2024. The increase in R&D expenses for the three months ended June 30, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount. General & Administrative (G&A) Expenses: G&A expenses were $6.7 million for the three months ended June 30, 2025 compared to $5.3 million for the three months ended June 30, 2024. The increase in G&A expenses for the three months ended June 30, 2025 was primarily driven by an increase in employee-related expenses due to an increase in stock-based compensation, headcount and other corporate expenses. Net Loss: Net loss was $22.0 million for the three months ended June 30, 2025 compared to $18.5 million for the three months ended June 30, 2024. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release are made as of the date of this press release. Neurogene does not undertake any obligation to make any updates to these statements to reflect events that occur or circumstances that arise after the date of this press release, except as may be required under applicable U.S. securities law. Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of NGN-401; trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial, and the timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial, anticipated timing of additional updates for the Embolden registrational trial of NGN-401 for Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome, expected future interactions with or positions of the FDA; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'on track,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things: the expected timing of additional results from the NGN-401 clinical trial; the potential for negative impacts to participants in the Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome; the risk that the Company may not be able to report data on the predicted timeline; risks related to the Company's ability to obtain regulatory approval for, and ultimately commercialize, its product candidates, including NGN-401; risks related to timing of initiating the Embolden trial of NGN-401 for Rett syndrome; and other risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission ('SEC') on August 11, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This communication contains hyperlinks to information that is not deemed to be incorporated by reference into this communication. - Financial Tables Follow - Neurogene Inc. Condensed Consolidated Statements of Operations (In thousands of U.S. dollars, except share information) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue under licensing agreements — 925 — 925 Operating expenses: Research and development expenses 19,366 15,744 37,131 29,285 General and administrative expenses 6,715 5,315 14,869 10,553 Total operating expenses 26,081 21,059 52,000 39,838 Loss from operations (26,081 ) (20,134 ) (52,000 ) (38,913 ) Other income, net 4,065 1,642 7,337 3,500 Net loss $ (22,016 ) $ (18,492 ) $ (44,663 ) $ (35,413 ) Per share information: Net loss per share, basic and diluted $ (1.05 ) $ (1.09 ) $ (2.12 ) $ (2.09 ) Weighted-average shares of common stock outstanding, basic and diluted 21,055,378 16,941,524 16,922,630 Expand
Yahoo
12 hours ago
- Yahoo
Red Hat OpenShift Named a Leader for Third Consecutive Year in 2025 Gartner® Magic Quadrant™ for Container Management
Red Hat is recognized as a Leader in the Magic Quadrant. Red Hat believes this affirms its foundational role in enterprise container strategies across the hybrid cloud. RALEIGH, N.C., August 11, 2025--(BUSINESS WIRE)--Red Hat, the world's leading provider of open source solutions, today announced that it has been named a Leader for the third consecutive year in the 2025 Gartner Magic Quadrant for Container Management. Red Hat OpenShift, the industry's leading hybrid cloud application platform powered by Kubernetes, was recognized for the solution's Completeness of Vision and in Ability to Execute in the Magic Quadrant. In our opinion, this consistent recognition highlights Red Hat OpenShift's unwavering ability to provide a comprehensive and robust platform for container management across diverse IT environments. It underscores Red Hat's commitment to offering operational consistency and standardization for organizations adopting cloud-native approaches. Red Hat OpenShift empowers enterprises to standardize, automate and scale their container initiatives across any footprint, from the datacenter to multiple cloud environments and the edge. The platform's integrated security features, advanced management capabilities and strong focus on developer productivity enable IT teams to accelerate application modernization and deliver business value more rapidly. The Gartner Magic Quadrant for Container Management evaluated 15 vendor solutions and was based on specific criteria that analyzed the company's overall completeness of vision and ability to execute. According to Gartner, Leaders execute well against their current vision and are well positioned for tomorrow. View a complimentary copy of the Magic Quadrant report to learn more about Red Hat's strengths and cautions, among other provider offerings, here. This report follows the Gartner recognition of the Red Hat as a Leader in the most recent 2025 Gartner Magic Quadrant for Cloud-Native Application Platforms. Supporting Quotes Mike Barrett, vice president & general manager, Hybrid Cloud Platforms, Red Hat "We believe being recognized as a Leader for the third consecutive year in the Gartner Magic Quadrant for Container Management validates Red Hat OpenShift's role as a cornerstone for modern IT strategies. Our platform empowers enterprises to standardize, automate and scale their container initiatives across any footprint, from the datacenter to multiple cloud environments, providing the flexibility and control needed to meet evolving business demands." Additional Resources Learn more about Red Hat OpenShift Check out the blog to learn more: Red Hat Named a Leader in 2025 Gartner® Magic Quadrant™ for Container Management for the Third Consecutive Year Connect with Red Hat Learn more about Red Hat Get more news in the Red Hat newsroom Read the Red Hat blog Follow Red Hat on X Follow Red Hat on Instagram Watch Red Hat videos on YouTube Follow Red Hat on LinkedIn Gartner Disclaimer Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. About Red Hat, Inc. Red Hat is the open hybrid cloud technology leader, delivering a trusted, consistent and comprehensive foundation for transformative IT innovation and AI applications. Its portfolio of cloud, developer, AI, Linux, automation and application platform technologies enables any application, anywhere—from the datacenter to the edge. As the world's leading provider of enterprise open source software solutions, Red Hat invests in open ecosystems and communities to solve tomorrow's IT challenges. Collaborating with partners and customers, Red Hat helps them build, connect, automate, secure and manage their IT environments, supported by consulting services and award-winning training and certification offerings. Forward-Looking Statements Except for the historical information and discussions contained herein, statements contained in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the company's current assumptions regarding future business and financial performance. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially. Any forward-looking statement in this press release speaks only as of the date on which it is made. Except as required by law, the company assumes no obligation to update or revise any forward-looking statements. Red Hat, Red Hat Enterprise Linux, the Red Hat logo, and OpenShift are trademarks or registered trademarks of Red Hat, Inc. or its subsidiaries in the U.S. and other countries. Linux® is the registered trademark of Linus Torvalds in the U.S. and other countries. View source version on Contacts Media Contact: Chelsea Lawrenceclawrenc@ +1 (252) 622-8406 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
